Corcept targets $3B-$5B Cushing's revenue by 2030 ahead of December 17 FDA decision
FROM THE WIRE · SEEKINGALPHA.COM
Corcept Q3 2026 earnings: revenue hit $340.5M as Lifyorli surged ahead of relacorilant's FDA decision.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe FDA decision on relacorilant is a relevant catalyst for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Corcept reported Q3 2026 revenue of $340.5M.
- 02Lifyorli surged ahead of the relacorilant FDA decision.
- 03The relacorilant FDA decision is expected December 17.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets